The venture-backed company, headquartered in Palo Alto, CA, which has developed a digital clinical trials platform, was selected to help drive enrollment of 1,050 patients across 20-40 sites.
The Phase IV pragmatic study will evaluate home versus office-based narrowband ultraviolet B phototherapy for psoriasis treatment.
“Medable’s technology solution ensures our patient and site facing apps integrate seamlessly into the busy schedules of our patients and researchers, leading to more complete and accurate data collection, as well as better patient enrollment and retention in our study,” said Dr. Joel M. Gelfand, lead study investigator, and professor of Dermatology and Epidemiology in the Perelman School of Medicine at University of Pennsylvania.
“We needed a partner that had the technical sophistication and experience necessary to customize the LITE study app to the needs of our patients and researchers, while providing the inter-operability to connect clinicians, researchers, and patients across our different sites,” he said in a statement.
Medable also earlier this month joined the American Heart Association (AHA) Center for Health Technology and Innovation Innovators Network.
The goal is to develop a ‘Human Heart Digitome,’ which is expected to be the largest real-world database dedicated to advancing cardiovascular disease research and patient care, Dr. Michelle Longmire, Medable co-founder and CEO, told us at the time.
Additionally, the National Cancer Institute (NCI) awarded the company two Fast-Track Small Business Innovation (SBIR) grants totaling up to $3.5m to further develop its end-to-end platform for digitally-enabled clinical trials.
